Adjuvant therapy in stage II thymic carcinoma

Area of Science:

• Oncology
• Thoracic Surgery
• Radiation Oncology

Background:

• Thymic carcinoma is a rare malignancy of the thymus.
• Stage II thymic carcinoma typically involves tumor invasion into surrounding mediastinal structures.
• Optimal adjuvant treatment strategies remain under investigation.

Purpose of the Study:

• To evaluate the impact of chemotherapy and/or radiotherapy on survival in patients with stage II thymic carcinoma.
• To determine if adjuvant therapies improve disease-free survival (DFS) and overall survival (OS).

Main Methods:

• Retrospective analysis of 31 patients with Masaoka stage II thymic carcinoma treated between 1995 and 2009.
• Kaplan-Meier method for survival curve analysis.
• Cox proportional hazard model for multivariate analysis.

Main Results:

• The 5-year DFS and OS rates were 74.6% and 89.5%, respectively.
• Squamous cell carcinoma was the most common subtype (48.4%).
• No statistically significant association was found between adjuvant radiotherapy/chemotherapy and DFS or OS.

Conclusions:

• Adjuvant therapy (chemotherapy and/or radiotherapy) after complete resection does not appear to impact survival outcomes in stage II thymic carcinoma.
• Further research may be needed to identify predictive factors for treatment response.